Latest From Thrombotargets Corp.
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Thrombotargets Corp.
- Senior Management
Javier Pedreno, MD, PhD, Pres. & CEO
Luis Acid, CFO
- Contact Info
Phone: (919) 806-4254
2530 Meridian Pkwy.
Durham, NC 27713
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.